Knowledge Center

Learn more about how you can accelerate your research with the WAVEsystem

Show filter options
Showing 125 of 125 resources

  • TechNote 1

    Sensitive kinetic analysis of small molecules binding to large drug targets

    In this TechNote we show how the WAVEsystem can be used to accurately monitor binding kinetics of large target-to-analyte molecular weight (MW) ratios (>300:1), thanks to the expanded sensing field over which the Grating-Coupled Interferometry (GCI) technology measures for high sensitivity.

  • Application Page

    Small Molecule Development

    Real is crude

    The Creoptix WAVEsystem provides a reliable environment for fragment-based drug discovery and small molecule screening, allowing for accurate off-rate kinetic analysis of crude reaction mixtures. With exquisite sensitivity, the ability to resolve extremely rapid dissociating kinetics, and innate compatibility with the high molecular weight ratios characteristic of most drug discovery programs, the Creoptix WAVEsystem improves fragment-based screening and kinetic analysis of small molecules to accelerate drug development.

  • TechNote 3

    Highly accurate resolution of fast off-rates to significantly reduce false-positives

    In this TechNote we show how the WAVEsystem can be used to accurately measure fast off-rate kinetics of weakly binding molecules. Thanks to a cartridge design that enables ultra-fast transition times of 150 ms, low potency hits can now be easily spotted for more successful drug discovery.

  • Publication

    E-Life, 2018

    W. Pitsawong, V. Buosi, R. Otten, R.V. Agafonov, A. Zorba, N. Kern, S. Kutter, G. Kern, R.A.P. Pádua, X. Meniche, D. Kern. "Dynamics of human protein kinase Aurora A linked to drug selectivity."

  • Publication

    Scientific Reports, 2020

    H. Jankovics, B. Kovacs, A. Saftics, T. Gerecsei, E. Tóth, I. Szekacs, F. Vonderviszt, R. Horvath. “Grating-coupled interferometry reveals binding kinetics and affinities of Ni ions to genetically engineered protein layers.”

  • TechNote 5

    Highly sensitive analysis at low immobilization levels, without mass transport limitation

    In this TechNote we show the remarkable sensitivity of the WAVEsystem. Thanks to the expanded sensing field over which the Grating-Coupled Interferometry (GCI) technology measures, high-resolution kinetic determination at even very low responses is possible, potentially reducing material costs significantly.

  • Virtual Seminar

    Small molecules: binding kinetics no matter the size

    • Screen, rank and characterize weak binders with off-rates up to 10 s-1.
    • Study binding kinetics even at large analyte:ligand MW ratios (up to 1:1000).
    • Experiment with crude mixtures, detergents and other additives without clogging.

  • Deck

    Binding kinetics on fibrils with label-free, surface-based sensors

    In collaboration with Istituto Mario Negri, Milano

    Alzheimer’s disease (AD) is the most common form of dementia in older people. This neurodegenerative
    disorder is characterized by the deposit of toxic b-amyloid plaques (amyloid fibrils) in the brain. b-Amyloid
    can interact with many intracellular and extracellular molecules, hence the importance of characterizing both
    binding affinity and kinetics of these interactions. With high sensitivity and the fastest off-rate resolution, the
    Creoptix WAVEsystem enables kinetic studies of weak binding THT (with off-rates of 10 s-1) onto amyloid fibrils.

  • Poster

    Spotting the weakest binders

    SLAS 2020

    Reliably determine off-rates of up to 10s-1, starting with just a crude reaction mixture. Work with a wide variety of solvents - including acetonitrile and high concentrations of DMSO - and minimize the occurrence of false positives.

  • TechNote 7

    Binding kinetics of a GPCR

    Membrane proteins are notoriously difficult to study due to the requirement for a membrane-mimicking environment and their instability once extracted from a cellular membrane. Here we show the capability of the WAVE to measure the interaction of a peptide ligand agonist (NTA11) with a thermostabilized variant of the neurotensin receptor 1 (NTSR1) at highest resolution.

  • TechNote 11

    Quick characterization of binding onto unpurified GPCRs

    In this TechNote, we show how the WAVEsystem can be used for the kinetic analysis of G-protein binding onto detergent-solubilized, unpurified GPCRs. By shortening a typical 10-step purification process, this method requires significantly less material (30mL of cell culture) and less time (less than 1 hour), thereby offering an alternative for screening purposes at an early stage of the drug discovery process involving membrane proteins.

  • Application Page

    Membrane Proteins

    Real is native

    Understanding the interaction between a membrane protein and a small molecule drug or monoclonal antibody therapeutic is fundamental to drug development since it provides valuable insight regarding drug potency and efficacy. Yet to fully understand such liaisons, it is vital that the measurement of binding kinetics between these molecules is reliable. With the sensitivity and versatility to measure analyte-membrane protein interactions in a wide variety of sample matrices, the Creoptix WAVEsystem enables more detailed investigation of membrane protein pharmacology, providing, for example, real-time drug binding affinities and label-free kinetics.

  • Interview

    Transforming drug discovery on membrane proteins

    Under the Microscope - Drug Target Review

    In November 2017, leadXpro chose to strengthen its capabilities with the Creoptix® WAVEsystem. “We were looking for a label‑free, biophysical method to investigate binding affinity and kinetics of small molecules with challenging integral membrane proteins,” explained Michael Hennig, Chief Executive Officer of leadXpro...

  • Virtual Seminar

    Binding kinetics onto membrane proteins

    • Analyze multiprotein complexes and even larger particles like VLPs and crude membranes.
    • WAVE goodbye to lengthy and laborious receptor purification procedures.
    • Welcome contaminants and work with crude samples.

  • Poster

    Keeping kinetics real

    PEGS Europe 2019

    Kinetic characterization of analytes binding to membrane proteins (GPCRs) embedded in virus-like particles (VLPs) and captured from crude cell membrane extracts (centrifugation-sonication).

  • TechNote 10

    Affinity and kinetics of antibodies in serum

    In this TechNote we show how the WAVE system can be used to accurately determine kinetics in serum. Thanks to a no-clog microfluidic design, kinetic studies can be performed under conditions that mimic the native environment as closely as possible, enabling the translation of these results to the clinic.

  • TechNote 12

    Antibody characterization from COVID-19 patient plasma binding to SARS-CoV-2 antigens

    In this TechNote, we show how the WAVEsystem can be used for the characterization of binding affinity and kinetics of antibodies raised against SARSCoV-2 in clinical human blood plasma samples. With innovative disposable, no-clog microfluidics and high sensitivity, the WAVEsystem opens the door for antibody characterization directly from clinical blood plasma samples. The methods described here are also compatible with high concentrations of serum and plasma of SARS-CoV-2 patients’ samples.

  • Application Page

    Serology

    Real is (less)diluted

    The Creoptix WAVEsystem combines superior resolution in signal and time with a crude-sample robustness normally only possible with plate-based assays. This provides dynamic, label free analysis of molecular interactions in a wide range of biofluids, providing full kinetic data that includes both affinity evaluation and highly accurate measurement of association and dissociation constants. Delivering a level of sensitivity superior to traditional Surface Plasmon Resonance (SPR) technologies, Creoptix’ proprietary Grating-Coupled Interferometry (GCI) technology is driving a new era of pharmacokinetics.

  • Poster

    Full kinetic characterization of antibodies in biofluids

    Immunotherapies and Innovations for Infectious Diseases 2019

    Assess antibody profiling in undiluted serum, measure kinetics in plasma and quantify anti-drug-antibody (ADA) titers directly from blood serum.

  • Webinar

    Early stage kinetics and validation of ELISA data

    • High-quality kinetics in a wide range of crude samples ranging from peptides to membrane proteins and relevant clinical samples.
    • WAVE goodbye to lengthy and laborious receptor purification procedures.
    • Welcome contaminants and work with crude samples.

  • Webinar

    Biochemical and biophysical characterization of biologics

    In collaboration with Shawn Owen (University of Utah)

    • Measuring kinetics in biofluids does provide valuable insights into a drug’s efficacy.
    • How can I best characterize antibody drug conjugates using biochemical and biophysical techniques?
    • Determination of level of payload and site of conjugation of ADCs using LC/MS.
    • Thermal stability and binding affinity of ADCs characterization using DSC, IR, ITC and GCI.
    • What is the Grating-Coupled Interferometry technology?

  • Podcast

    Sybody® candidates compete for ACE2 binding onto SARS-CoV-2 Spike RBD

    Rapid kinetic characterization for inhibition assays

    Listen to Markus Seeger (University of Zurich) and Rony Nehmé (Creoptix) discuss binding affinities and selectivity of Sybody® candidates to the receptor-binding domain (RBD) region of SARS-CoV-2 Spike protein. Highlights:

    • Why ELISA signals alone are not enough to predict potency in biologics development
    • Why did Markus choose the WAVEsystem for the biomolecular interaction analysis at his lab?
    • Why choosing the right candidates at the very early stages of research matters.

  • Poster

    Augmented affinity in antibody-antigen interactions: impact on design of diagnostic assays

    Presented by Mologic at PEGS Boston 2019

    Anti-p24 antibody binding kinetics were measured using the Creoptix WAVEdelta system. The results of this study reveal a surprising enhancement in affinity due to a significant 21-fold increase in on-rate when anti-p24 mAb1 recognizes the anti-p24 mAb2-p24 complex.

  • Application Page

    Biologics Development

    Real is natural

    The Creoptix® WAVEsystem enables researchers to study biologic drugs in a wide range of biofluids and other complex matrices. With superior sensitivity to traditional Surface Plasmon Resonance (SPR) technologies for more accurate measurement of binding affinity and binding kinetics, the Creoptix WAVEsystem is driving biologics development.

  • Publication

    bioRxiv, 2020

    J. D. Walter, C. A. J. Hutter, A. A. Garaeva, M. Scherer, I. Zimmermann, M. Wyss, J. Rheinberger, Y. Ruedin, J. C. Earp, P. Egloff, M. Sorgenfrei, L. Hürlimann, I. Gonda, G. Meier, S. Remm, S. Thavarasah, G. Zimmer, D. J. Slotboom, C. Paulino, P. Plattet, M. A. Seeger. “Highly potent bispecific sybodies neutralize SARS-CoV-2.”

  • Publication

    Journal of Molecular Biology, 2019

    F. Andres, L. Iamele, T. Meyer, J.C. Stüber, F. Kast, E. Gherardi, H.H. Niemann, A. Plückthun. "Inhibition of the MET Kinase Activity and Cell Growth in MET-Addicted Cancer Cells by Bi-Paratopic Linking."

  • TechNote 14

    Shedding light on Sybody® candidates binding onto SARS-CoV-2 spike RBD

    In this TechNote we show how the WAVE system can be used to understand the binding dynamics of Sybody® candidates to the receptor binding domain (RBD) of SARS-CoV-2, both provided by Linkster Therapeutics AG and the University of Zürich. With high sensitivity and robust microfluidics, the WAVEsystem is suitable for competition assays, confirming and enriching ELISA data. By providing a rapid kinetic characterization for inhibition assays, with ACE2 kindly provided by leadXpro, the WAVE is accelerating the development of therapeutics against SARS-CoV-2.

  • Publication

    bioRxiv, 2020

    J. D. Walter, C. A. .J. Hutter, I. Zimmermann, M. Wyss, P. Egloff, M. Sorgenfrei, L. M. Hürlimann, I. Gonda, G. Meier, S. Remm, S. Thavarasah, P. Plattet, M. A. Seeger. “Sybodies targeting the SARS-CoV-2 receptor-binding domain.”

  • Poster

    A physicochemical approach to characterizing antibody-drug conjugates through stability into target validation

    PEGSBoston Virtual 2020 - Waters & Collaborators

    A panel of methods were used to establish comprehensive characterization of antibody-drug conjugates (ADCs), including liquid chromatography, mass spectrometry, size exclusion chromatography, microfluidic modulation spectroscopy, differential scanning calorimetry, grating-coupled interferometry (GCI) and isothermal titration calorimetry.

  • Webinar

    Binding kinetics supporting peptide discovery

    In collaboration with Pepscan

    • Optimization of peptides for therapeutic and diagnostic purposes.
    • Off-rate screening as a valuable alternative approach to small molecule fragments and peptide selection in drug discovery.
    • GCI technology can be used as orthogonal validation technique for ELISA data.
    • Measuring kinetics in biofluids provides valuable insights into a drug’s efficacy.
    • CLIPS® as a powerful and bio-orthogonal peptide cross linking chemistry.

  • Webinar

    Early stage kinetics and validation of ELISA data

    • High-quality kinetics in a wide range of crude samples ranging from peptides to membrane proteins and relevant clinical samples.
    • WAVE goodbye to lengthy and laborious receptor purification procedures.
    • Welcome contaminants and work with crude samples.

  • Webinar

    Biochemical and biophysical characterization of biologics

    In collaboration with Shawn Owen (University of Utah)

    • Measuring kinetics in biofluids does provide valuable insights into a drug’s efficacy.
    • How can I best characterize antibody drug conjugates using biochemical and biophysical techniques?
    • Determination of level of payload and site of conjugation of ADCs using LC/MS.
    • Thermal stability and binding affinity of ADCs characterization using DSC, IR, ITC and GCI.
    • What is the Grating-Coupled Interferometry technology?

  • Poster

    Real samples, real data

    PEGS Europe 2019

    Assess antibody profiling in undiluted biofluids for reliable kinetic profiling in conditions closer to real life. Study kinetics in aggregating proteins (fibrils).

  • Webinar

    Binding kinetics supporting peptide discovery

    In collaboration with Pepscan

    • Optimization of peptides for therapeutic and diagnostic purposes.
    • Off-rate screening as a valuable alternative approach to small molecule fragments and peptide selection in drug discovery.
    • GCI technology can be used as orthogonal validation technique for ELISA data.
    • Measuring kinetics in biofluids provides valuable insights into a drug’s efficacy.
    • CLIPS® as a powerful and bio-orthogonal peptide cross linking chemistry.

  • Publication

    PNAS, 2020

    S. Moussu, C. Broyart, G. Santos-Fernandez, S. Augustin, S. Wehrle, U. Grossniklaus, J. Santiago. "Structural basis for recognition of RALF peptides by LRX proteins during pollen tube growth."

  • Poster

    Discovery of CLIPS binders to anti-TNFa mAb’s using phage display libraries

    Presented by Pepscan

    Here we report the use of a monocyclic phage library encoding for a fully randomized 10-
    mer peptide sequence flanked by two cysteines that are linked via a CLIPSTM scaffold to identify peptide binders that bind to Infliximab. Binding assessed with the WAVEsystem.

  • Webinar

    Early stage kinetics and validation of ELISA data

    • High-quality kinetics in a wide range of crude samples ranging from peptides to membrane proteins and relevant clinical samples.
    • WAVE goodbye to lengthy and laborious receptor purification procedures.
    • Welcome contaminants and work with crude samples.

  • Publication

    The EMBO Journal, 2019

    K. Lau, R. Podolec, R. Chappuis, R. Ulm, M. Hothorn. "Plant photoreceptors and their signaling components compete for binding to the ubiquitin ligase COP1 using their VP-peptide motifs."

  • Publication

    PNAS, 2020

    S. Okuda, S. Fujita, A. Moretti, U. Hohmann, V.G. Doblas, Y. Ma, A. Pfister, B. Brandt, N. Geldner, M. Hothorn. "Molecular mechanism for the recognition of sequence-divergent CIF peptides by the plant receptor kinases GSO1/SGN3 and GSO2."

  • Publication

    PNAS, 2020

    A. D. Crook, A. C. Willoughby, O. Hazak, S. Okuda, K. R. VanDerMolen, C. L. Soyars, P. Cattaneo, N. M. Clark, R. Sozzani, M. Hothorn, C. S. Hardtke, Z. L. Nimchuk. “BAM1/2 receptor kinase signaling drives CLE peptide-mediated formative cell divisions in Arabidopsis roots.”

  • Small Molecule/FBDD

    Sensitive kinetic analysis of small molecules binding to large drug targets

    In this TechNote we show how the WAVEsystem can be used to accurately monitor binding kinetics of large target-to-analyte molecular weight (MW) ratios (>300:1), thanks to the expanded sensing field over which the Grating-Coupled Interferometry (GCI) technology measures for high sensitivity.

  • Small Molecule/FBDD

    Highly accurate resolution of fast off-rates to significantly reduce false-positives

    In this TechNote we show how the WAVEsystem can be used to accurately measure fast off-rate kinetics of weakly binding molecules. Thanks to a cartridge design that enables ultra-fast transition times of 150 ms, low potency hits can now be easily spotted for more successful drug discovery.

  • Small Molecule/FBDD

    Highly sensitive analysis at low immobilization levels, without mass transport limitation

    In this TechNote we show the remarkable sensitivity of the WAVEsystem. Thanks to the expanded sensing field over which the Grating-Coupled Interferometry (GCI) technology measures, high-resolution kinetic determination at even very low responses is possible, potentially reducing material costs significantly.

  • Membrane Proteins

    Binding kinetics of a GPCR

    Membrane proteins are notoriously difficult to study due to the requirement for a membrane-mimicking environment and their instability once extracted from a cellular membrane. Here we show the capability of the WAVE to measure the interaction of a peptide ligand agonist (NTA11) with a thermostabilized variant of the neurotensin receptor 1 (NTSR1) at highest resolution.

  • Serology

    Affinity and kinetics of antibodies in serum

    In this TechNote we show how the WAVE system can be used to accurately determine kinetics in serum. Thanks to a no-clog microfluidic design, kinetic studies can be performed under conditions that mimic the native environment as closely as possible, enabling the translation of these results to the clinic.

  • Membrane Proteins

    Quick characterization of binding onto unpurified GPCRs

    In this TechNote, we show how the WAVEsystem can be used for the kinetic analysis of G-protein binding onto detergent-solubilized, unpurified GPCRs. By shortening a typical 10-step purification process, this method requires significantly less material (30mL of cell culture) and less time (less than 1 hour), thereby offering an alternative for screening purposes at an early stage of the drug discovery process involving membrane proteins.

  • Serology

    Antibody characterization from COVID-19 patient plasma binding to SARS-CoV-2 antigens

    In this TechNote, we show how the WAVEsystem can be used for the characterization of binding affinity and kinetics of antibodies raised against SARSCoV-2 in clinical human blood plasma samples. With innovative disposable, no-clog microfluidics and high sensitivity, the WAVEsystem opens the door for antibody characterization directly from clinical blood plasma samples. The methods described here are also compatible with high concentrations of serum and plasma of SARS-CoV-2 patients’ samples.

  • Biologics

    Shedding light on Sybody® candidates binding onto SARS-CoV-2 spike RBD

    In this TechNote we show how the WAVE system can be used to understand the binding dynamics of Sybody® candidates to the receptor binding domain (RBD) of SARS-CoV-2, both provided by Linkster Therapeutics AG and the University of Zürich. With high sensitivity and robust microfluidics, the WAVEsystem is suitable for competition assays, confirming and enriching ELISA data. By providing a rapid kinetic characterization for inhibition assays, with ACE2 kindly provided by leadXpro, the WAVE is accelerating the development of therapeutics against SARS-CoV-2.

  • Small Molecules/FBDD

    Small molecules: binding kinetics no matter the size

    • Screen, rank and characterize weak binders with off-rates up to 10 s-1.
    • Study binding kinetics even at large analyte:ligand MW ratios (up to 1:1000).
    • Experiment with crude mixtures, detergents and other additives without clogging.

  • Peptides

    Early stage kinetics and validation of ELISA data

    • High-quality kinetics in a wide range of crude samples ranging from peptides to membrane proteins and relevant clinical samples.
    • WAVE goodbye to lengthy and laborious receptor purification procedures.
    • Welcome contaminants and work with crude samples.

  • Membrane Proteins

    Binding kinetics onto membrane proteins

    • Analyze multiprotein complexes and even larger particles like VLPs and crude membranes.
    • WAVE goodbye to lengthy and laborious receptor purification procedures.
    • Welcome contaminants and work with crude samples.

  • Serology

    Biochemical and biophysical characterization of biologics

    In collaboration with Shawn Owen (University of Utah)

    • Measuring kinetics in biofluids does provide valuable insights into a drug’s efficacy.
    • How can I best characterize antibody drug conjugates using biochemical and biophysical techniques?
    • Determination of level of payload and site of conjugation of ADCs using LC/MS.
    • Thermal stability and binding affinity of ADCs characterization using DSC, IR, ITC and GCI.
    • What is the Grating-Coupled Interferometry technology?

  • Serology

    Early stage kinetics and validation of ELISA data

    • High-quality kinetics in a wide range of crude samples ranging from peptides to membrane proteins and relevant clinical samples.
    • WAVE goodbye to lengthy and laborious receptor purification procedures.
    • Welcome contaminants and work with crude samples.

  • Peptides

    Binding kinetics supporting peptide discovery

    In collaboration with Pepscan

    • Optimization of peptides for therapeutic and diagnostic purposes.
    • Off-rate screening as a valuable alternative approach to small molecule fragments and peptide selection in drug discovery.
    • GCI technology can be used as orthogonal validation technique for ELISA data.
    • Measuring kinetics in biofluids provides valuable insights into a drug’s efficacy.
    • CLIPS® as a powerful and bio-orthogonal peptide cross linking chemistry.

  • Biologics Development

    Biochemical and biophysical characterization of biologics

    In collaboration with Shawn Owen (University of Utah)

    • Measuring kinetics in biofluids does provide valuable insights into a drug’s efficacy.
    • How can I best characterize antibody drug conjugates using biochemical and biophysical techniques?
    • Determination of level of payload and site of conjugation of ADCs using LC/MS.
    • Thermal stability and binding affinity of ADCs characterization using DSC, IR, ITC and GCI.
    • What is the Grating-Coupled Interferometry technology?

  • Biologics Development

    Binding kinetics supporting peptide discovery

    In collaboration with Pepscan

    • Optimization of peptides for therapeutic and diagnostic purposes.
    • Off-rate screening as a valuable alternative approach to small molecule fragments and peptide selection in drug discovery.
    • GCI technology can be used as orthogonal validation technique for ELISA data.
    • Measuring kinetics in biofluids provides valuable insights into a drug’s efficacy.
    • CLIPS® as a powerful and bio-orthogonal peptide cross linking chemistry.

  • Biologics Development

    Early stage kinetics and validation of ELISA data

    • High-quality kinetics in a wide range of crude samples ranging from peptides to membrane proteins and relevant clinical samples.
    • WAVE goodbye to lengthy and laborious receptor purification procedures.
    • Welcome contaminants and work with crude samples.

  • Plant Sciences

    Probing signalling interactions by two methods: GCI and ITC

    Biophysical methods applied to signalling interactions, including those in plant sciences by Kelvin Lau (Protein Production and Structure Core Facility (PTPSP, EPFL)

    In this series of virtual seminar, we will walk you through the benefits of the WAVEsystem for plant sciences research. Expect to see high-quality kinetics in the toughest sample conditions!

  • Small Molecules/FBDD

    Scientific Reports, 2020

    H. Jankovics, B. Kovacs, A. Saftics, T. Gerecsei, E. Tóth, I. Szekacs, F. Vonderviszt, R. Horvath. “Grating-coupled interferometry reveals binding kinetics and affinities of Ni ions to genetically engineered protein layers.”

  • Plant Sciences

    PNAS, 2020

    A. D. Crook, A. C. Willoughby, O. Hazak, S. Okuda, K. R. VanDerMolen, C. L. Soyars, P. Cattaneo, N. M. Clark, R. Sozzani, M. Hothorn, C. S. Hardtke, Z. L. Nimchuk. “BAM1/2 receptor kinase signaling drives CLE peptide-mediated formative cell divisions in Arabidopsis roots.”

  • COVID-19 Research

    bioRxiv, 2020

    J. D. Walter, C. A. J. Hutter, A. A. Garaeva, M. Scherer, I. Zimmermann, M. Wyss, J. Rheinberger, Y. Ruedin, J. C. Earp, P. Egloff, M. Sorgenfrei, L. Hürlimann, I. Gonda, G. Meier, S. Remm, S. Thavarasah, G. Zimmer, D. J. Slotboom, C. Paulino, P. Plattet, M. A. Seeger. “Highly potent bispecific sybodies neutralize SARS-CoV-2.”

  • Biologics Development

    bioRxiv, 2020

    J. D. Walter, C. A. .J. Hutter, I. Zimmermann, M. Wyss, P. Egloff, M. Sorgenfrei, L. M. Hürlimann, I. Gonda, G. Meier, S. Remm, S. Thavarasah, P. Plattet, M. A. Seeger. “Sybodies targeting the SARS-CoV-2 receptor-binding domain.”

  • Peptides

    PNAS, 2020

    A. D. Crook, A. C. Willoughby, O. Hazak, S. Okuda, K. R. VanDerMolen, C. L. Soyars, P. Cattaneo, N. M. Clark, R. Sozzani, M. Hothorn, C. S. Hardtke, Z. L. Nimchuk. “BAM1/2 receptor kinase signaling drives CLE peptide-mediated formative cell divisions in Arabidopsis roots.”

  • COVID-19 Research

    bioRxiv, 2020

    J. D. Walter, C. A. .J. Hutter, I. Zimmermann, M. Wyss, P. Egloff, M. Sorgenfrei, L. M. Hürlimann, I. Gonda, G. Meier, S. Remm, S. Thavarasah, P. Plattet, M. A. Seeger. “Sybodies targeting the SARS-CoV-2 receptor-binding domain.”

  • Plant Sciences

    Plant Physiology, 2020

    P. Jimenez Sandoval, J. Santiago. “In vitro analytical approaches to study plant ligand-receptor interactions.”

  • Peptides

    PNAS, 2020

    S. Moussu, C. Broyart, G. Santos-Fernandez, S. Augustin, S. Wehrle, U. Grossniklaus, J. Santiago. "Structural basis for recognition of RALF peptides by LRX proteins during pollen tube growth."

  • Biologics Development

    bioRxiv, 2020

    J. D. Walter, C. A. J. Hutter, A. A. Garaeva, M. Scherer, I. Zimmermann, M. Wyss, J. Rheinberger, Y. Ruedin, J. C. Earp, P. Egloff, M. Sorgenfrei, L. Hürlimann, I. Gonda, G. Meier, S. Remm, S. Thavarasah, G. Zimmer, D. J. Slotboom, C. Paulino, P. Plattet, M. A. Seeger. “Highly potent bispecific sybodies neutralize SARS-CoV-2.”

  • Plant Sciences

    Science, 2020

    N. M. Doll, S. Royek, S. Fujita, S. Okuda, S. Chamot, A. Stintzi, T. Widiez, M. Hothorn, A. Schaller, N. Geldner. "A two-way molecular dialogue between embryo and endosperm is required for seed development."

  • Plant Sciences

    PNAS, 2020

    S. Okuda, S. Fujita, A. Moretti, U. Hohmann, V.G. Doblas, Y. Ma, A. Pfister, B. Brandt, N. Geldner, M. Hothorn. "Molecular mechanism for the recognition of sequence-divergent CIF peptides by the plant receptor kinases GSO1/SGN3 and GSO2."

  • Plant Sciences

    PNAS, 2020

    S. Moussu, C. Broyart, G. Santos-Fernandez, S. Augustin, S. Wehrle, U. Grossniklaus, J. Santiago. "Structural basis for recognition of RALF peptides by LRX proteins during pollen tube growth."

  • Protein-Protein Interactions

    Analyst, 2019

    B. Peter, A. Saftics, B. Kovacs, S. Kurunczi, R. Horvath. "Oxidation increases the binding of EGCG to serum albumin revealed by kinetic data from label-free optical biosensor with reference channel."

  • Plant Sciences

    The EMBO Journal, 2019

    K. Lau, R. Podolec, R. Chappuis, R. Ulm, M. Hothorn. "Plant photoreceptors and their signaling components compete for binding to the ubiquitin ligase COP1 using their VP-peptide motifs."

  • Peptides

    PNAS, 2020

    S. Okuda, S. Fujita, A. Moretti, U. Hohmann, V.G. Doblas, Y. Ma, A. Pfister, B. Brandt, N. Geldner, M. Hothorn. "Molecular mechanism for the recognition of sequence-divergent CIF peptides by the plant receptor kinases GSO1/SGN3 and GSO2."

  • Peptides

    The EMBO Journal, 2019

    K. Lau, R. Podolec, R. Chappuis, R. Ulm, M. Hothorn. "Plant photoreceptors and their signaling components compete for binding to the ubiquitin ligase COP1 using their VP-peptide motifs."

  • Biologics Development

    Journal of Molecular Biology, 2019

    F. Andres, L. Iamele, T. Meyer, J.C. Stüber, F. Kast, E. Gherardi, H.H. Niemann, A. Plückthun. "Inhibition of the MET Kinase Activity and Cell Growth in MET-Addicted Cancer Cells by Bi-Paratopic Linking."

  • Plant Sciences

    Life Science Alliance Journal, 2019

    L. Lorenzo-Orts, U. Hohmann, J. Zhu, M. Hothorn. "Molecular characterization of CHAD domains as inorganic polyphosphate-binding modules."

  • Plant Sciences

    Nature Plants, 2018

    
U. Hohmann, J. Nicolet, A. Moretti, L.A. Hothorn, M. Hothorn, "The SERK3 elongated allele defines a role for BIR ectodomains in brassinosteroid signalling."

  • Plant Sciences

    PNAS, 2018

    U. Hohmann, J. Santiago, J. Nicolet, V. Olsson, F. Spiga. L.A. Hothorn, M.A. Butenko, M. Hothorn, "Mechanistic basis for the activation of plant membrane receptor kinases by SERK-family coreceptors."

  • Small Molecules/FBDD

    E-Life, 2018

    W. Pitsawong, V. Buosi, R. Otten, R.V. Agafonov, A. Zorba, N. Kern, S. Kutter, G. Kern, R.A.P. Pádua, X. Meniche, D. Kern. "Dynamics of human protein kinase Aurora A linked to drug selectivity."

  • Real is crude

    Small Molecule Development

    The Creoptix WAVEsystem provides a reliable environment for fragment-based drug discovery and small molecule screening, allowing for accurate off-rate kinetic analysis of crude reaction mixtures. With exquisite sensitivity, the ability to resolve extremely rapid dissociating kinetics, and innate compatibility with the high molecular weight ratios characteristic of most drug discovery programs, the Creoptix WAVEsystem improves fragment-based screening and kinetic analysis of small molecules to accelerate drug development.

  • Real is native

    Membrane Proteins

    Understanding the interaction between a membrane protein and a small molecule drug or monoclonal antibody therapeutic is fundamental to drug development since it provides valuable insight regarding drug potency and efficacy. Yet to fully understand such liaisons, it is vital that the measurement of binding kinetics between these molecules is reliable. With the sensitivity and versatility to measure analyte-membrane protein interactions in a wide variety of sample matrices, the Creoptix WAVEsystem enables more detailed investigation of membrane protein pharmacology, providing, for example, real-time drug binding affinities and label-free kinetics.

  • Real is (less)diluted

    Serology

    The Creoptix WAVEsystem combines superior resolution in signal and time with a crude-sample robustness normally only possible with plate-based assays. This provides dynamic, label free analysis of molecular interactions in a wide range of biofluids, providing full kinetic data that includes both affinity evaluation and highly accurate measurement of association and dissociation constants. Delivering a level of sensitivity superior to traditional Surface Plasmon Resonance (SPR) technologies, Creoptix’ proprietary Grating-Coupled Interferometry (GCI) technology is driving a new era of pharmacokinetics.

  • Real is natural

    Biologics Development

    The Creoptix® WAVEsystem enables researchers to study biologic drugs in a wide range of biofluids and other complex matrices. With superior sensitivity to traditional Surface Plasmon Resonance (SPR) technologies for more accurate measurement of binding affinity and binding kinetics, the Creoptix WAVEsystem is driving biologics development.

  • Real is relevant

    COVID-19 Research

    SARS-CoV-2 proved challenging in ways current technologies were unable to address, limiting studies to extrapolations and inferences. It’s through innovation and technologies like the Creoptix® WAVEsystem that advance discovery and understanding. The drive to know more, study every angle, and make every measurement. With the ability to measure fast transitions in undiluted crude samples, all within a disposable cartridge, the WAVE makes challenging studies possible.

  • Real samples, real data

    WAVEsystem

    The WAVE of the future in kinetics

    Confidently detect and quantify biological interactions in real-time, for high-quality kinetic data across a broader range of samples than traditional equipment.

    The Creoptix WAVEsystem puts a breakthrough level of kinetics analysis at your fingertips by pushing the boundaries of affinity range and sample compatibility. The system’s exceptionally high data quality, sample compatibility and automated software facilitates drug discovery and enable new inroads into R&D.

  • A sensor chip for every need

    WAVEchips

    Robust microfluidics for a broad range of applications

    • Explore any biomolecular interaction with a broad range of sensor chip surfaces for an all-in-one solution.
    • Perform your experiments in biofluids (including serum and plasma), crude samples and uncommon solvents thanks to our no-clog microfluidics design for reduced maintenance costs.
    • Exchange your WAVEchips to have fresh, clean microfluidics within minutes, without the need for special technical support.
    • Enjoy the fastest and most synchronized sample transitions thanks to our parallel flow channels for high-quality kinetics.

  • Fast, intuitive, automated

    WAVEcontrol

    Workflow-based design offering both flexibility and functionality

    1. waveRAPID® – Kinetics in hours instead of days
      RAPID stands for Repeated Analyte Pulses of Increasing Duration. This new way of measuring kinetics allows you to probe the interaction of interest using injections from a single well, with short pulses of increasing duration.
    2. Direct Kinetics - Automated, objective way of evaluating data
      We rely on robust statistical estimators to deliver an automated calculation of your kinetic parameters with a mathematically sound error analysis.

  • Smooth operations

    WAVEcare

    Carefree or basic support for high-quality kinetic data and unparalleled performance

    The different WAVEcare programs ensure the continuous, high performance operation of your WAVEsystem. Choose the program that fits your needs.

    1. Carefree Program: for the regular user
      Know what you are up to and plan your maintenance budget ahead of time
    2. Basic Program: for the occasional user
      Call us when you need us the most for a PM visit or a repair

  • Biologics Development

    A physicochemical approach to characterizing antibody-drug conjugates through stability into target validation

    PEGSBoston Virtual 2020 - Waters & Collaborators

    A panel of methods were used to establish comprehensive characterization of antibody-drug conjugates (ADCs), including liquid chromatography, mass spectrometry, size exclusion chromatography, microfluidic modulation spectroscopy, differential scanning calorimetry, grating-coupled interferometry (GCI) and isothermal titration calorimetry.

  • Small Molecules/FBDD

    Spotting the weakest binders

    SLAS 2020

    Reliably determine off-rates of up to 10s-1, starting with just a crude reaction mixture. Work with a wide variety of solvents - including acetonitrile and high concentrations of DMSO - and minimize the occurrence of false positives.

  • Biologics Development

    Augmented affinity in antibody-antigen interactions: impact on design of diagnostic assays

    Presented by Mologic at PEGS Boston 2019

    Anti-p24 antibody binding kinetics were measured using the Creoptix WAVEdelta system. The results of this study reveal a surprising enhancement in affinity due to a significant 21-fold increase in on-rate when anti-p24 mAb1 recognizes the anti-p24 mAb2-p24 complex.

  • Membrane Proteins

    Keeping kinetics real

    PEGS Europe 2019

    Kinetic characterization of analytes binding to membrane proteins (GPCRs) embedded in virus-like particles (VLPs) and captured from crude cell membrane extracts (centrifugation-sonication).

  • Peptides

    Discovery of CLIPS binders to anti-TNFa mAb’s using phage display libraries

    Presented by Pepscan

    Here we report the use of a monocyclic phage library encoding for a fully randomized 10-
    mer peptide sequence flanked by two cysteines that are linked via a CLIPSTM scaffold to identify peptide binders that bind to Infliximab. Binding assessed with the WAVEsystem.

  • Biologics Development

    Real samples, real data

    PEGS Europe 2019

    Assess antibody profiling in undiluted biofluids for reliable kinetic profiling in conditions closer to real life. Study kinetics in aggregating proteins (fibrils).

  • Serology

    Full kinetic characterization of antibodies in biofluids

    Immunotherapies and Innovations for Infectious Diseases 2019


    Assess antibody profiling in undiluted serum, measure kinetics in plasma and quantify anti-drug-antibody (ADA) titers directly from blood serum.

  • Plant Sciences

    GCI: a new method for label-free protein interaction studies

    Plants, Peptides and Receptors in Málaga 2018


    Here we characterize the interactions of various plant leucine-rich repeat receptor kinases (LRR-RKs) with their cognate ligands and SERK-family co-receptors using a label-free surface biosensor based on grating-coupled interferometry (GCI). Due to the comparably low amount of recombinant protein and analyte needed, GCI is an excellent alternative for experiments where key components are scarce.

  • Biologics Development

    Sybody® candidates compete for ACE2 binding onto SARS-CoV-2 Spike RBD

    Rapid kinetic characterization for inhibition assays

    Listen to Markus Seeger (University of Zurich) and Rony Nehmé (Creoptix) discuss binding affinities and selectivity of Sybody® candidates to the receptor-binding domain (RBD) region of SARS-CoV-2 Spike protein. Highlights:

    • Why ELISA signals alone are not enough to predict potency in biologics development
    • Why did Markus choose the WAVEsystem for the biomolecular interaction analysis at his lab?
    • Why choosing the right candidates at the very early stages of research matters.

  • Grating-coupled interferometry

    It's how we see light

    Determine kinetics, affinity, and concentrations of interacting molecules with high sensitivity

    Grating-Coupled Interferometry (GCI) is based on waveguide interferometry to determine kinetics, affinity, and concentrations of the interacting molecules. Similar to other optical label-free methods, such as surface plasmon resonance (SPR), the target (or ligand) is immobilized to the sensor surface and the analyte is flowed over the surface in what is called the bulk. Light is coupled to the surface creating an evanescent field. Interactions are detected by the resulting change in mass and thus a change in the refractive index.

  • No-clog microfluidic design

    It's how we flow

    Valveless microfluidics for fast transitions

    The valveless design enables ultra-fast transition times of 150 msec for reliable determination of off-rates of 10 s–1 (half-life of 69 ms), enabling accurate off-rate kinetics of weakly binding fragments and low affinity antibodies.

    No-clog microfluidics accommodates of a broad range of sample types to preserve activity and biological context, saving time from detrimental purification steps and clogging that takes other systems offline, including 100% whole blood or undiluted serum and plasma, cell supernatant, cell membrane preps, virus-like particles (VLPs), liposomes, viscous detergents, DMSO and acetonitrile.

  • Analyze Creoptix data in Genedata Screener

    Genedata Ready-to-Run

    Genedata and Creoptix offer a Ready-to-Run integration, allowing you to analyze data prepared with a Creoptix instrument in your Genedata Screener®.

    The joint solution offers:

    • Direct analysis of Grating-Coupled Interferometry in Genedata Screener.
    • Sample data association across systems and characterization techniques.
    • Reduced set-up and routine analysis times.

  • Small Molecules/FBDD

    Binding kinetics on fibrils with label-free, surface-based sensors

    In collaboration with Istituto Mario Negri, Milano

    Alzheimer’s disease (AD) is the most common form of dementia in older people. This neurodegenerative
    disorder is characterized by the deposit of toxic b-amyloid plaques (amyloid fibrils) in the brain. b-Amyloid
    can interact with many intracellular and extracellular molecules, hence the importance of characterizing both
    binding affinity and kinetics of these interactions. With high sensitivity and the fastest off-rate resolution, the
    Creoptix WAVEsystem enables kinetic studies of weak binding THT (with off-rates of 10 s-1) onto amyloid fibrils.

  • Keeping kinetics real

    Specs WAVEsystem

    Highlights

    • waveRAPID - kinetics in hours instead of days (WAVEdelta only)
    • Crude samples, harsh chemicals, and particles up to 1000 nm
    • Self-contained disposable cartridge and small footprint
    • Ultra-fast transition times of 150 ms with reliable determination of off-rates up to 10 s-1
    • Superior signal-to-noise ratios (0.01 pg/mm2 at 1 Hz)
    • Reliable kinetics and binding affinities (KD) from low pM to low mM with from signals below 1 pg/mm2
    • Analyze large ligand‑to‑analyte molecular weight ratios up to >1000:1
    • Up to 120 hours of unattended operation

  • Find the right WAVEchip for your application

    WAVEchip Quickstart Guide

    WAVEchips®- Innovative design and patented microfluidic cartridge to support crude samples, pathogenic samples, harsh solvents, and large particles up to 1000 nm normally only achieved with plate-based assays for kinetic analysis not possible before.

    Explore any biomolecular interaction with a broad range of sensor chip surfaces for an all-in-one solution.

  • Make the most out of your WAVEsystem

    Recommended vendors for consumables and reagents - EU

    EU Edition

    Everything our specialists recommend using when setting up experiments with your WAVEsystem:

    • Well plates
    • Reagents
    • Vials & caps
    • Foils

  • Make the most out of your WAVEsystem

    Recommended vendors for consumables and reagents - US

    US Edition

    Everything our specialists recommend using when setting up experiments with your WAVEsystem:

    • Well plates
    • Reagents
    • Vials & caps
    • Foils

  • Membrane Proteins

    Transforming drug discovery on membrane proteins

    Under the Microscope - Drug Target Review

    In November 2017, leadXpro chose to strengthen its capabilities with the Creoptix® WAVEsystem. “We were looking for a label‑free, biophysical method to investigate binding affinity and kinetics of small molecules with challenging integral membrane proteins,” explained Michael Hennig, Chief Executive Officer of leadXpro...

  • Poster

    Augmented affinity in antibody-antigen interactions: impact on design of diagnostic assays

    Presented by Mologic at PEGS Boston 2019

    Anti-p24 antibody binding kinetics were measured using the Creoptix WAVEdelta system. The results of this study reveal a surprising enhancement in affinity due to a significant 21-fold increase in on-rate when anti-p24 mAb1 recognizes the anti-p24 mAb2-p24 complex.

  • Publication

    Nature Plants, 2018

    
U. Hohmann, J. Nicolet, A. Moretti, L.A. Hothorn, M. Hothorn, "The SERK3 elongated allele defines a role for BIR ectodomains in brassinosteroid signalling."

  • Poster

    GCI: a new method for label-free protein interaction studies

    Plants, Peptides and Receptors in Málaga 2018


    Here we characterize the interactions of various plant leucine-rich repeat receptor kinases (LRR-RKs) with their cognate ligands and SERK-family co-receptors using a label-free surface biosensor based on grating-coupled interferometry (GCI). Due to the comparably low amount of recombinant protein and analyte needed, GCI is an excellent alternative for experiments where key components are scarce.

  • Publication

    PNAS, 2020

    S. Moussu, C. Broyart, G. Santos-Fernandez, S. Augustin, S. Wehrle, U. Grossniklaus, J. Santiago. "Structural basis for recognition of RALF peptides by LRX proteins during pollen tube growth."

  • Publication

    Science, 2020

    N. M. Doll, S. Royek, S. Fujita, S. Okuda, S. Chamot, A. Stintzi, T. Widiez, M. Hothorn, A. Schaller, N. Geldner. "A two-way molecular dialogue between embryo and endosperm is required for seed development."

  • Webinar

    Probing signalling interactions by two methods: GCI and ITC

    Biophysical methods applied to signalling interactions, including those in plant sciences by Kelvin Lau (Protein Production and Structure Core Facility (PTPSP, EPFL)

    In this series of virtual seminar, we will walk you through the benefits of the WAVEsystem for plant sciences research. Expect to see high-quality kinetics in the toughest sample conditions!

  • Publication

    Plant Physiology, 2020

    P. Jimenez Sandoval, J. Santiago. “In vitro analytical approaches to study plant ligand-receptor interactions.”

  • Publication

    The EMBO Journal, 2019

    K. Lau, R. Podolec, R. Chappuis, R. Ulm, M. Hothorn. "Plant photoreceptors and their signaling components compete for binding to the ubiquitin ligase COP1 using their VP-peptide motifs."

  • Publication

    Life Science Alliance Journal, 2019

    L. Lorenzo-Orts, U. Hohmann, J. Zhu, M. Hothorn. "Molecular characterization of CHAD domains as inorganic polyphosphate-binding modules."

  • Publication

    PNAS, 2020

    S. Okuda, S. Fujita, A. Moretti, U. Hohmann, V.G. Doblas, Y. Ma, A. Pfister, B. Brandt, N. Geldner, M. Hothorn. "Molecular mechanism for the recognition of sequence-divergent CIF peptides by the plant receptor kinases GSO1/SGN3 and GSO2."

  • Publication

    PNAS, 2018

    U. Hohmann, J. Santiago, J. Nicolet, V. Olsson, F. Spiga. L.A. Hothorn, M.A. Butenko, M. Hothorn, "Mechanistic basis for the activation of plant membrane receptor kinases by SERK-family coreceptors."

  • Publication

    PNAS, 2020

    A. D. Crook, A. C. Willoughby, O. Hazak, S. Okuda, K. R. VanDerMolen, C. L. Soyars, P. Cattaneo, N. M. Clark, R. Sozzani, M. Hothorn, C. S. Hardtke, Z. L. Nimchuk. “BAM1/2 receptor kinase signaling drives CLE peptide-mediated formative cell divisions in Arabidopsis roots.”

  • Podcast

    Sybody® candidates compete for ACE2 binding onto SARS-CoV-2 Spike RBD

    Rapid kinetic characterization for inhibition assays

    Listen to Markus Seeger (University of Zurich) and Rony Nehmé (Creoptix) discuss binding affinities and selectivity of Sybody® candidates to the receptor-binding domain (RBD) region of SARS-CoV-2 Spike protein. Highlights:

    • Why ELISA signals alone are not enough to predict potency in biologics development
    • Why did Markus choose the WAVEsystem for the biomolecular interaction analysis at his lab?
    • Why choosing the right candidates at the very early stages of research matters.

  • TechNote 12

    Antibody characterization from COVID-19 patient plasma binding to SARS-CoV-2 antigens

    In this TechNote, we show how the WAVEsystem can be used for the characterization of binding affinity and kinetics of antibodies raised against SARSCoV-2 in clinical human blood plasma samples. With innovative disposable, no-clog microfluidics and high sensitivity, the WAVEsystem opens the door for antibody characterization directly from clinical blood plasma samples. The methods described here are also compatible with high concentrations of serum and plasma of SARS-CoV-2 patients’ samples.

  • Application Page

    COVID-19 Research

    Real is relevant

    SARS-CoV-2 proved challenging in ways current technologies were unable to address, limiting studies to extrapolations and inferences. It’s through innovation and technologies like the Creoptix® WAVEsystem that advance discovery and understanding. The drive to know more, study every angle, and make every measurement. With the ability to measure fast transitions in undiluted crude samples, all within a disposable cartridge, the WAVE makes challenging studies possible.

  • Publication

    bioRxiv, 2020

    J. D. Walter, C. A. J. Hutter, A. A. Garaeva, M. Scherer, I. Zimmermann, M. Wyss, J. Rheinberger, Y. Ruedin, J. C. Earp, P. Egloff, M. Sorgenfrei, L. Hürlimann, I. Gonda, G. Meier, S. Remm, S. Thavarasah, G. Zimmer, D. J. Slotboom, C. Paulino, P. Plattet, M. A. Seeger. “Highly potent bispecific sybodies neutralize SARS-CoV-2.”

  • TechNote 14

    Shedding light on Sybody® candidates binding onto SARS-CoV-2 spike RBD

    In this TechNote we show how the WAVE system can be used to understand the binding dynamics of Sybody® candidates to the receptor binding domain (RBD) of SARS-CoV-2, both provided by Linkster Therapeutics AG and the University of Zürich. With high sensitivity and robust microfluidics, the WAVEsystem is suitable for competition assays, confirming and enriching ELISA data. By providing a rapid kinetic characterization for inhibition assays, with ACE2 kindly provided by leadXpro, the WAVE is accelerating the development of therapeutics against SARS-CoV-2.

  • Publication

    bioRxiv, 2020

    J. D. Walter, C. A. .J. Hutter, I. Zimmermann, M. Wyss, P. Egloff, M. Sorgenfrei, L. M. Hürlimann, I. Gonda, G. Meier, S. Remm, S. Thavarasah, P. Plattet, M. A. Seeger. “Sybodies targeting the SARS-CoV-2 receptor-binding domain.”

  • Webinar

    Early stage kinetics and validation of ELISA data

    • High-quality kinetics in a wide range of crude samples ranging from peptides to membrane proteins and relevant clinical samples.
    • WAVE goodbye to lengthy and laborious receptor purification procedures.
    • Welcome contaminants and work with crude samples.

  • Real Samples, Real Data

    The Creoptix WAVEsystem

    Confidently detect and quantify biological interactions in real-time, for high-quality kinetic data across a broader range of samples than traditional equipment.

    Product Teaser

Discover more content